Verrica Pharmaceuticals announced positive topline results from its Phase III CAMP-1 and CAMP-2 pivotal trials with VP 102 (cantharidin 0.7%)...
Verrica Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for VP 102 (cantharidin 0.7% Topical Solution), a...
Verrica Pharmaceuticals Inc. announced that the Company received a letter from the FDA as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for VP 102 (cantharidin 0.7% topical solution), Verrica’s lead product candidate for the treatment of molluscum contagiosum.
Verrica Pharmaceuticals Inc. presented data from the company’s pivotal Phase III CAMP-1 and CAMP-2 trials of lead product candidate, VP...
Verrica Pharmaceuticals Inc. announced that the FDA has issued a Complete Response Letter regarding its New Drug Application (NDA) for VP 102 for the treatment of molluscum contagiosum (molluscum).
Verrica Pharmaceuticals Inc. has announced that the FDA has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP 102 for the treatment of molluscum contagiosum (molluscum).
Purpose: ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC).
This statement provides an overview of the state-of-the art in AHP, by means of a concise overview of AHP pathophysiology, clinical manifestations, and burden of disease, (Belgian) epidemiology, treatments, and proposed organization of care.
Vanda Pharmaceuticals Inc. announced results from its Phase III clinical study, VP-VLY-686-3303 , evaluating the efficacy and safety of tradipitant in treating the symptoms of gastroparesis.
As a calcium sensitizer and inodilator that augments cardiac contractility without increasing myocardial oxygen demand or exacerbating ischaemia, levosimendan may be well configured to deliver inotropic support in cases of acute heart failure (AHF).